Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban.

@article{Nakano2015ClinicalUO,
  title={Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban.},
  author={Yoshihisa Nakano and Takahisa Kondo and Hiroyuki Osanai and Yosuke Murase and Yoshihito Nakashima and Hiroshi Asano and Masayoshi Ajioka and Kazuyoshi Sakai and Yasuya Inden and Toyoaki Murohara},
  journal={Journal of cardiology},
  year={2015},
  volume={65 3},
  pages={185-90}
}
BACKGROUND Rivaroxaban is currently used to prevent stroke in patients with atrial fibrillation. Measuring coagulation function may help clinicians to understand the effects of this drug and the associated risk of bleeding. METHODS AND RESULTS Rivaroxaban was given to 136 patients with non-valvular atrial fibrillation. Mean age was 74.5±9.0 years (men: 63.2%) and mean CHADS2 score (±SD) was 1.8±1.2. Prothrombin times (PTs) and plasma soluble fibrin (SF) levels were examined in 84 out of 136… CONTINUE READING